Earnings ·
Charles River Reports Q3 Revenue of $982.7M and Raises Full-Year EPS Guidance
CRLCharles River Laboratories International, Inc.
Charles River Laboratories International reported third-quarter revenue of $982.7 million, a 2.2% decrease from the prior year period primarily due to divestitures, but with organic revenue growth of 4.7%. GAAP diluted earnings per share were $6.86, significantly higher than $1.10 in the same quarter last year, driven by a $245.6 million benefit from the reversal of acquired tax reserves. Non-GAAP diluted EPS increased 27.2% to $3.09. The company raised its full-year 2026 guidance for both revenue and non-GAAP earnings per share, citing third-quarter outperformance in the Discovery and Safety Assessment segment and a lower effective tax rate. Charles River Laboratories provides essential products and services to help pharmaceutical and biotechnology companies accelerate research and drug development efforts.